There are 19 resources available
Should VEGFR TKI + CPI Combination be the Standard 1st Line Systemic Therapy for all Metastatic RCC Patients? YES
Presenter: T. Rajasekaran, SG
Session: SESSION 4 – Debate of the Day
Resources:
Slides
Webcast
Should VEGFR TKI + CPI Combination be the Standard 1st Line Systemic Therapy for all Metastatic RCC Patients? NO
Presenter: L. Albiges, FR
Session: SESSION 4 – Debate of the Day
Resources:
Slides
Webcast
Bladder Cancer
Presenter: A. Bamias, GR
Session: SESSION 5 – Personalized Therapy in Metastatic Bladder Cancer and RCC
Resources:
Slides
Webcast
RCC
Presenter: L. Albiges, FR
Session: SESSION 5 – Personalized Therapy in Metastatic Bladder Cancer and RCC
Resources:
Slides
Webcast
Chemotherapy
Presenter: R. Kanesvaran, SG
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
Tyrosine Kinase Inhibitors and mTOR Inhibitors in RCC
Presenter: T. Rajasekaran, SG
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
Immunotherapy
Presenter: L. Albiges, FR
Session: SESSION 6 - Side Effects
Resources:
Webcast
Participants Clinical Case Discussion: 4 Years Survival of mRCC Without Immunotherapy
Presenter: V. Talreja, IN
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
Participants Clinical Case Discussion: Treatment of Metastatic RCC Patient with Hepatotoxicity
Presenter: B. Oztosun, TR
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast